U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27NO2
Molecular Weight 337.4553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINEPTINE

SMILES

OC(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=ONNOFKFOZAJDHT-UHFFFAOYSA-N
InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)

HIDE SMILES / InChI

Molecular Formula C22H27NO2
Molecular Weight 337.4553
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Survector

Approved Use

Survector 100mg tablet is used in the treatment of depression.

Launch Date

2.52460794E11
PubMed

PubMed

TitleDatePubMed
[The problem of side-effects: cardiotoxicity (author's transl)].
1981
[Hepatitis, cholestasis and amineptine (author's transl)].
1981 Dec 18-25
[Hepatitis caused by amineptine : a case with reintroduction of the drug].
1981 Nov
[Hepatitis due to amineptin. 4 cases].
1982 Nov
[Rosaceous drug eruption caused by amineptin (Survector)].
1988
[Acneiform eruption induced by amineptin (Survector)].
1989
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case].
1991 Dec
[Immediate acute hepatic cytolysis after the administration of a single amineptin tablet].
1992
The serotonin syndrome.
1992 Oct
[Acne induced by amineptin: adnexal toxiderma].
1996
Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study.
1997 Sep
[A case of Parkinson syndrome secondary to combined amineptine and bromazepam abuse].
1998 Sep-Oct
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
2001
Acneiform eruption caused by amineptine. A case report and review of the literature.
2001 Jul
Social stress in anorexia nervosa: a review of immuno-endocrine relationships.
2001 Jun
Dopaminergic augmentation of sleep deprivation effects in bipolar depression.
2001 Nov 30
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002 Dec
WHO Expert Committee on Drug Dependence.
2003
Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.
2003
Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice.
2003 Jul
Sex-dependent modulation of treatment response.
2004 Mar
Fluoxetine dependence in a former amineptine abuser.
2004 Oct-Dec
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate.
2006 Dec
Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides.
2007 Dec 31
Addressing the paradoxes of satisfaction with hospital care.
2008
Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse.
2008 Sep
Improving pain management communication: how patients understand the terms "opioid" and "narcotic".
2008 Sep
Treatment for amphetamine withdrawal.
2009 Apr 15
[Acne induced by amineptine].
2009 Jan-Feb
A new strategy for antidepressant prescription.
2010
Management of anorexia and bulimia nervosa: An evidence-based review.
2010 Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
2010 Dec
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/21584062
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration: Oral
In Vitro Use Guide
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Substance Class Chemical
Created
by admin
on Fri Dec 16 20:02:35 UTC 2022
Edited
by admin
on Fri Dec 16 20:02:35 UTC 2022
Record UNII
27T1I13L6G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINEPTINE
INN   MI   WHO-DD  
INN  
Official Name English
7-((10,11-DIHYDRO-5H-DIBENZO(A,D)CYCLOHEPTEN-5-YL)AMINO)HEPTANOIC ACID
Systematic Name English
AMINEPTINE [MI]
Common Name English
AMINEPTIN
Common Name English
Amineptine [WHO-DD]
Common Name English
amineptine [INN]
Common Name English
Classification Tree Code System Code
WHO-VATC QN06AA19
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
WHO-ATC N06AA19
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
NCI_THESAURUS C265
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
Code System Code Type Description
EPA CompTox
DTXSID1048831
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
RXCUI
17698
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY RxNorm
INN
3998
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
WIKIPEDIA
AMINEPTINE
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
MESH
C011597
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
MERCK INDEX
M1673
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY Merck Index
CHEBI
32499
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
EVMPD
SUB05435MIG
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
NCI_THESAURUS
C74142
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
ECHA (EC/EINECS)
260-818-0
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
PUBCHEM
34870
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
FDA UNII
27T1I13L6G
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
DRUG CENTRAL
161
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
ChEMBL
CHEMBL418995
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
CAS
57574-09-1
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
DRUG BANK
DB04836
Created by admin on Fri Dec 16 20:02:35 UTC 2022 , Edited by admin on Fri Dec 16 20:02:35 UTC 2022
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY